URGN – UroGen Pharma Ltd.

UroGen Pharma Ltd.

URGN

$26.10

Name : UroGen Pharma Ltd.

Sector : Healthcare

Industry: Biotechnology

Mark. Cap: $1,280,148,224.00

EPSttm : -1.31

UroGen Pharma Ltd.

$26.10

3.08%

$0.78

URGN — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

12.26

Margin Of Safety %

Put/Call OI Ratio

0.23

EPS Next Q Diff

0.43

EPS Last/This Y

2.99

EPS This/Next Y

2.96

Price

26.07

Target Price

60.71

Analyst Recom

Performance Q

-45.76

Upside

-278.4%

Beta

1.68

Ticker: URGN

22 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-10-13	URGN	38.24	0.74	0.11	7753
2026-10-14	URGN	36.58	0.73	0.24	7841
2026-10-15	URGN	36.58	0.69	0.07	8176
2026-10-16	URGN	34.53	0.67	11.09	8092
2026-10-19	URGN	34.13	0.48	0.04	6519
2026-10-20	URGN	34.98	0.44	0.10	6925
2026-10-21	URGN	35.49	0.44	0.02	6978
2026-10-22	URGN	35.12	0.44	0.00	6957
2026-10-23	URGN	34.55	0.43	0.05	7004
2026-10-26	URGN	34.03	0.43	0.05	6992
2026-10-27	URGN	33.92	0.43	21.50	7028
2026-10-28	URGN	33.78	0.56	0.19	7658
2026-10-29	URGN	33.53	0.44	0.31	8936
2026-10-30	URGN	32.7	0.44	0.11	8990
2026-11-02	URGN	34.39	0.44	0.03	9008
2026-11-03	URGN	34.42	0.44	0.15	9023
2026-11-04	URGN	28.74	0.43	0.06	9261
2026-11-05	URGN	25.76	0.39	0.01	9868
2026-11-06	URGN	24.76	0.33	0.15	10185
2026-11-09	URGN	26.32	0.33	0.00	10265
2026-11-10	URGN	25.31	0.27	0.01	12083
2026-11-11	URGN	26.12	0.23	0.06	13627
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

22 items 1 of 1

22 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-10-13	URGN	38.24	113.3	-	-0.24
2026-10-14	URGN	36.57	113.3	-	-0.24
2026-10-15	URGN	36.59	113.3	-	-0.24
2026-10-16	URGN	34.53	113.3	-	-0.24
2026-10-19	URGN	34.13	113.3	-	-0.24
2026-10-20	URGN	34.13	113.3	-	-0.24
2026-10-21	URGN	34.99	113.3	-	-0.24
2026-10-22	URGN	35.12	113.3	-	-0.24
2026-10-23	URGN	34.54	113.3	-	-0.24
2026-10-26	URGN	34.03	113.3	-	-0.24
2026-10-27	URGN	33.92	113.3	-	-0.24
2026-10-28	URGN	33.77	113.3	-	-0.24
2026-10-29	URGN	33.50	113.3	-	-0.24
2026-10-30	URGN	32.72	113.3	-	-0.24
2026-11-02	URGN	34.38	113.3	-	-0.24
2026-11-03	URGN	34.43	113.3	-	-0.24
2026-11-04	URGN	28.72	114.0	-	-0.24
2026-11-05	URGN	25.74	114.0	-	-0.24
2026-11-06	URGN	24.75	180.2	-	-0.20
2026-11-09	URGN	26.32	180.2	-	-0.20
2026-11-10	URGN	25.31	180.2	-	-0.20
2026-11-11	URGN	26.07	180.2	-	-0.20
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

22 items 1 of 1

21 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-10-13	URGN	-1.34	-0.93	18.71
2026-10-14	URGN	-1.34	-0.93	18.71
2026-10-15	URGN	-1.34	-0.93	18.72
2026-10-16	URGN	-1.34	-0.93	18.72
2026-10-19	URGN	-1.34	1.19	18.72
2026-10-20	URGN	-1.34	1.19	18.72
2026-10-21	URGN	-1.34	1.19	18.72
2026-10-22	URGN	-1.34	1.19	18.72
2026-10-23	URGN	-1.34	1.19	18.72
2026-10-26	URGN	-1.34	1.25	18.72
2026-10-27	URGN	-1.34	1.25	13.51
2026-10-28	URGN	-1.34	1.25	13.51
2026-10-29	URGN	-1.34	1.25	13.51
2026-10-30	URGN	-1.34	1.25	13.51
2026-11-02	URGN	-1.34	0.17	13.51
2026-11-03	URGN	-1.34	0.17	13.51
2026-11-05	URGN	-1.34	0.17	13.51
2026-11-06	URGN	-1.34	0.17	13.51
2026-11-09	URGN	-1.34	-0.70	13.46
2026-11-10	URGN	-1.34	-0.70	13.46
2026-11-11	URGN	-1.34	-0.70	12.26
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

21 items 1 of 1

Last Quarter Act. EPS

-0.03

Avg. EPS Est. Current Quarter

0.42

Avg. EPS Est. Next Quarter

0.4

Insider Transactions

-1.34

Institutional Transactions

-0.7

Beta

1.68

Average Sales Estimate Current Quarter

108

Average Sales Estimate Next Quarter

113

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

48.7

Max Drawdown 5-Year %

-82.6

Target Price

60.71

P/E

Forward P/E

10.46

PEG

P/S

5.12

P/B

P/Free Cash Flow

EPS

-1.33

Average EPS Est. Cur. Y

-0.2

EPS Next Y. (Est.)

2.76

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-26.27

Relative Volume

0.73

Return on Equity vs Sector %

26.1

Return on Equity vs Industry %

45.7

EPS 1 7Days Diff

EPS 1 30Days Diff

0.04

EBIT Estimation

◆ URGN Healthcare

$26.10

📉

Swing / Pullback

Buy the dip on strong trends

N/A

WEAK

Trend

2/20

Pullback

9/25

Volume

6/15

Valuation

15/20

TP/AR

6/10

Options

6/10

RSI

27.8

Range 1M

10.1%

Sup Dist

5.2%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

6/25

Growth

25/30

Estimates

5/20

Inst/Vol

1/15

Options

10/10

EPS Yr

88.5%

EPS NY

777.1%

52W%

27.4%

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

🟢 BUY +230.8% upside

Quality

7/30

Valuation

16/30

Growth

19/25

Stability

8/10

LT Trend

1/5

Upside

+230.8%

Quality

URGN — P/E HistoricalBiotechnology

UroGen Pharma Ltd.

Sector: Healthcare

Industry: Biotechnology

Employees: 300

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions. The company's lead product candidates are UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk NMIBC. It is also developing UGN-301, UGN-301+UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is headquartered in Princeton, New Jersey.

URGN

Latest News

—

Caricamento notizie per URGN…

stock quote shares URGN – UroGen Pharma Ltd. Stock Price stock today

news today URGN – UroGen Pharma Ltd. stock forecast ,stock prediction 2023 2024 2025

marketwatch URGN – UroGen Pharma Ltd. yahoo finance google finance

stock history URGN – UroGen Pharma Ltd. invest stock market

stock prices URGN premarket after hours

ticker URGN fair value insiders trading

URGN – UroGen Pharma Ltd.

UroGen Pharma Ltd.

URGN

$26.10

Name : UroGen Pharma Ltd.

Sector : Healthcare

Industry: Biotechnology

Mark. Cap: $1,280,148,224.00

EPSttm : -1.31

UroGen Pharma Ltd.

$26.10

3.08%

$0.78

URGN — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

12.26

Margin Of Safety %

Put/Call OI Ratio

0.23

EPS Next Q Diff

0.43

EPS Last/This Y

2.99

EPS This/Next Y

2.96

Price

26.07

Target Price

60.71

Analyst Recom

Performance Q

-45.76

Upside

-278.4%

Beta

1.68

Ticker: URGN

22 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-10-13	URGN	38.24	0.74	0.11	7753
2026-10-14	URGN	36.58	0.73	0.24	7841
2026-10-15	URGN	36.58	0.69	0.07	8176
2026-10-16	URGN	34.53	0.67	11.09	8092
2026-10-19	URGN	34.13	0.48	0.04	6519
2026-10-20	URGN	34.98	0.44	0.10	6925
2026-10-21	URGN	35.49	0.44	0.02	6978
2026-10-22	URGN	35.12	0.44	0.00	6957
2026-10-23	URGN	34.55	0.43	0.05	7004
2026-10-26	URGN	34.03	0.43	0.05	6992
2026-10-27	URGN	33.92	0.43	21.50	7028
2026-10-28	URGN	33.78	0.56	0.19	7658
2026-10-29	URGN	33.53	0.44	0.31	8936
2026-10-30	URGN	32.7	0.44	0.11	8990
2026-11-02	URGN	34.39	0.44	0.03	9008
2026-11-03	URGN	34.42	0.44	0.15	9023
2026-11-04	URGN	28.74	0.43	0.06	9261
2026-11-05	URGN	25.76	0.39	0.01	9868
2026-11-06	URGN	24.76	0.33	0.15	10185
2026-11-09	URGN	26.32	0.33	0.00	10265
2026-11-10	URGN	25.31	0.27	0.01	12083
2026-11-11	URGN	26.12	0.23	0.06	13627
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

22 items 1 of 1

22 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-10-13	URGN	38.24	113.3	-	-0.24
2026-10-14	URGN	36.57	113.3	-	-0.24
2026-10-15	URGN	36.59	113.3	-	-0.24
2026-10-16	URGN	34.53	113.3	-	-0.24
2026-10-19	URGN	34.13	113.3	-	-0.24
2026-10-20	URGN	34.13	113.3	-	-0.24
2026-10-21	URGN	34.99	113.3	-	-0.24
2026-10-22	URGN	35.12	113.3	-	-0.24
2026-10-23	URGN	34.54	113.3	-	-0.24
2026-10-26	URGN	34.03	113.3	-	-0.24
2026-10-27	URGN	33.92	113.3	-	-0.24
2026-10-28	URGN	33.77	113.3	-	-0.24
2026-10-29	URGN	33.50	113.3	-	-0.24
2026-10-30	URGN	32.72	113.3	-	-0.24
2026-11-02	URGN	34.38	113.3	-	-0.24
2026-11-03	URGN	34.43	113.3	-	-0.24
2026-11-04	URGN	28.72	114.0	-	-0.24
2026-11-05	URGN	25.74	114.0	-	-0.24
2026-11-06	URGN	24.75	180.2	-	-0.20
2026-11-09	URGN	26.32	180.2	-	-0.20
2026-11-10	URGN	25.31	180.2	-	-0.20
2026-11-11	URGN	26.07	180.2	-	-0.20
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

22 items 1 of 1

21 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-10-13	URGN	-1.34	-0.93	18.71
2026-10-14	URGN	-1.34	-0.93	18.71
2026-10-15	URGN	-1.34	-0.93	18.72
2026-10-16	URGN	-1.34	-0.93	18.72
2026-10-19	URGN	-1.34	1.19	18.72
2026-10-20	URGN	-1.34	1.19	18.72
2026-10-21	URGN	-1.34	1.19	18.72
2026-10-22	URGN	-1.34	1.19	18.72
2026-10-23	URGN	-1.34	1.19	18.72
2026-10-26	URGN	-1.34	1.25	18.72
2026-10-27	URGN	-1.34	1.25	13.51
2026-10-28	URGN	-1.34	1.25	13.51
2026-10-29	URGN	-1.34	1.25	13.51
2026-10-30	URGN	-1.34	1.25	13.51
2026-11-02	URGN	-1.34	0.17	13.51
2026-11-03	URGN	-1.34	0.17	13.51
2026-11-05	URGN	-1.34	0.17	13.51
2026-11-06	URGN	-1.34	0.17	13.51
2026-11-09	URGN	-1.34	-0.70	13.46
2026-11-10	URGN	-1.34	-0.70	13.46
2026-11-11	URGN	-1.34	-0.70	12.26
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

21 items 1 of 1

Last Quarter Act. EPS

-0.03

Avg. EPS Est. Current Quarter

0.42

Avg. EPS Est. Next Quarter

0.4

Insider Transactions

-1.34

Institutional Transactions

-0.7

Beta

1.68

Average Sales Estimate Current Quarter

108

Average Sales Estimate Next Quarter

113

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

48.7

Max Drawdown 5-Year %

-82.6

Target Price

60.71

P/E

Forward P/E

10.46

PEG

P/S

5.12

P/B

P/Free Cash Flow

EPS

-1.33

Average EPS Est. Cur. Y

-0.2

EPS Next Y. (Est.)

2.76

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-26.27

Relative Volume

0.73

Return on Equity vs Sector %

26.1

Return on Equity vs Industry %

45.7

EPS 1 7Days Diff

EPS 1 30Days Diff

0.04

EBIT Estimation

◆ URGN Healthcare

$26.10

📉

Swing / Pullback

Buy the dip on strong trends

N/A

WEAK

Trend

2/20

Pullback

9/25

Volume

6/15

Valuation

15/20

TP/AR

6/10

Options

6/10

RSI

27.8

Range 1M

10.1%

Sup Dist

5.2%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

6/25

Growth

25/30

Estimates

5/20

Inst/Vol

1/15

Options

10/10

EPS Yr

88.5%

EPS NY

777.1%

52W%

27.4%

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

🟢 BUY +230.8% upside

Quality

7/30

Valuation

16/30

Growth

19/25

Stability

8/10

LT Trend

1/5

Upside

+230.8%

Quality

URGN — P/E HistoricalBiotechnology

UroGen Pharma Ltd.

Sector: Healthcare

Industry: Biotechnology

Employees: 300

URGN

Latest News

—

Caricamento notizie per URGN…

stock quote shares URGN – UroGen Pharma Ltd. Stock Price stock today

news today URGN – UroGen Pharma Ltd. stock forecast ,stock prediction 2023 2024 2025

marketwatch URGN – UroGen Pharma Ltd. yahoo finance google finance

stock history URGN – UroGen Pharma Ltd. invest stock market

stock prices URGN premarket after hours

ticker URGN fair value insiders trading

URGN – UroGen Pharma Ltd.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: URGN

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Latest News

URGN – UroGen Pharma Ltd.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: URGN

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

Last Quarter Act. EPS

Average EPS Est. Cur. Y

Last Quarter Act. EPS

Average EPS Est. Cur. Y